Reprint
Advances in Diagnosis and Therapy of Neuroendocrine Neoplasms
Edited by
January 2021
144 pages
- ISBN978-3-03943-745-0 (Hardback)
- ISBN978-3-03943-746-7 (PDF)
This is a Reprint of the Special Issue Advances in Diagnosis and Therapy of Neuroendocrine Neoplasms that was published in
Medicine & Pharmacology
Public Health & Healthcare
Summary
This Special Issue is dedicated to neuroendocrine neoplasms (NENs), a category of malignancy that demonstrates wide clinical heterogeneity, posing major challenges in diagnosis and management. There have been significant advances in the field of NEN genomics, pathology, imaging, and treatment over the past five years. NENs are examples of rare tumours (although their incidence and prevalence are increasing) where international collaborative efforts have allowed the generation of high-level evidence to guide optimal patient-centred care. This issue presents both reviews and original papers to provide comprehensive state-of-the-art understanding of this fascinating disease.
Format
- Hardback
License and Copyright
© 2022 by the authors; CC BY-NC-ND license
Keywords
small bowel neuroendocrine tumours; pancreatic neuroendocrine tumours; liver metastases; midgut; meta-analysis; neuroendocrine tumors; carcinoid heart disease; carcinoid syndrome; somatostatin analogues; metastases; neuroendocrine tumors; multidisciplinary; management; outcome; grading; staging; neuroendocrine neoplasms; chemotherapy; temozolomide; metronomic treatment; second-line; neuroendocrine neoplasms; NOTCH; cancer-driven genes; mutational mechanism; germline mutations; small cell lung carcinoma; pancreatic NET; small bowel NET; medullary thyroid carcinoma; malignant castration-resistant prostatic cells; quality performance indicators; QPIs; cancer care; neuroendocrine tumour; NETs; modified Delphi; CommNETs; pancreatic neuroendocrine neoplasms; neuroendocrine tumor; long-term functional outcomes; pancreatectomy; diabetes mellitus; pancreatic exocrine insufficiency; body mass index; parenchyma-sparing surgery; neuroendocrine tumours; neuroendocrine neoplasms; curative surgery; resection; follow-up; guidelines; relapse; recurrence; risk factor; mixed non-neuroendocrine neuroendocrine neoplasms; MiNENs; mixed adeno-neuroendocrine carcinoma; MANEC; 2017 WHO classification; 2019 WHO classification